文献速递骨肿瘤骨质疏松与代谢性骨病

朗格汉斯细胞组织细胞增生症成人患者停用地舒单抗后骨转换无过度反弹:一项前瞻性临床试验

No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial.
PubMed 文献 · Osteoporos Int · 2025-05-26

这项前瞻性、单臂、开放标签2b期临床试验纳入10例成人朗格汉斯细胞组织细胞增生症患者,其中8例有骨病变(4例单发、4例多发)、2例无骨病变,给予地舒单抗皮下注射120 mg/2个月共6个月(总480 mg),末次注射后随访24个月。治疗使骨转换标志物降至治疗前约10%,停药后峰值未超过治疗前水平;平均(±SD)峰值血清CTX为0.522±0.366 ng/mL、P1NP为72.2±35.9 ng/mL,与基线无显著差异(p分别为0.11和0.65)。未观察到椎体骨折、骨量丢失或高钙血症,作者认为地舒单抗总剂量不是停药后骨转换过度反弹的重要决定因素。

要点

  • 10例成人朗格汉斯细胞组织细胞增生症患者接受地舒单抗120 mg/2个月共6个月(总480 mg)。
  • 停药后骨转换标志物峰值未超过治疗前水平,CTX与P1NP较基线均无显著差异。
  • 未观察到椎体骨折、骨量丢失或高钙血症,地舒单抗总剂量不是骨转换过度反弹的重要决定因素。

核心结论

  • 朗格汉斯细胞组织细胞增生症患者停用地舒单抗后未出现骨转换标志物过度反弹或骨量丢失,尽管6个月内给予的总剂量相当于骨质疏松治疗4年的总剂量。
  • 地舒单抗总剂量不是治疗停止后骨转换过度反弹的重要决定因素。

研究设计与样本

  • 前瞻性、单臂、开放标签、2b期临床试验,纳入10例成人朗格汉斯细胞组织细胞增生症患者,其中8例有骨病变(4例单发、4例多发)、2例无骨病变。
  • 地舒单抗皮下注射120 mg/2个月共6个月(总480 mg),末次注射后随访24个月。

主要发现

  • 治疗使骨转换标志物降至治疗前约10%,停药后峰值未超过治疗前水平。
  • 平均(±SD)峰值血清CTX为0.522±0.366 ng/mL,P1NP为72.2±35.9 ng/mL,与基线无显著差异(p分别为0.11和0.65)。
  • 治疗前与峰值血清CTX显著相关(rs=0.818,p=0.007)。
  • 未观察到椎体骨折、骨量丢失或高钙血症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Denosumab (Dmab) discontinuation in osteoporosis leads to overshoot (rebound) of bone turnover, but its cause remains largely unclear. In a prospective trial, Dmab-treated Langerhans cell histiocytosis (LCH) patients showed no overshoot of bone turnover markers despite high short-term dosing. Findings suggest that total Dmab dose does not drive the overshoot of bone turnover markers. PURPOSE: In patients with osteoporosis, the length of treatment with denosumab (Dmab) is an important risk factor for the overshoot (rebound) of bone turnover markers following its discontinuation. Whether this is due to the higher total Dmab dose given and/or the severity of the disease is unknown. To address this question, long-term follow-up of changes in bone metabolism after stopping Dmab with doses higher than those used in osteoporosis is essential. METHODS: In a prospective, single-arm, open label, phase 2b clinical trial, ten adult patients with Langerhans cell histiocytosis (LCH), eight with bone lesions (four single, four multiple) and two without, were treated with Dmab sc injections 120 mg/2 months for 6 months (total 480 mg) and were followed for 24 months after the last injection. RESULTS: Treatment reduced bone turnover markers to about 10% of pretreatment values, which increased after treatment arrest to a peak that did not exceed pretreatment levels; mean (± SD) peak serum CTX 0.522 ± 0.366 ng/mL and P1NP 72.2 ± 35.9 ng/mL were not significantly different from baseline (p = 0.11 and 0.65, respectively). Moreover, pretreatment and peak serum CTX values were significantly correlated (rs = 0.818, p = 0.007). No vertebral fractures, bone loss, or hypercalcemia were observed. CONCLUSION: Dmab withdrawal in patients with LCH was not followed by an overshoot of bone turnover markers or bone loss despite the administration in 6 months of a total dose equal to that given in osteoporosis for 4 years. Total Dmab dose is, thus, not an important determinant of the bone turnover overshoot after treatment withdrawal.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Makras P, Yavropoulou MP, Anastasilakis AD, et al. No overshoot of bone turnover after withdrawal of denosumab treatment of adults with Langerhans cell histiocytosis: a prospective clinical trial. Osteoporos Int. 2025. PMID: 40418338. doi:10.1007/s00198-025-07538-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。